» Articles » PMID: 29686017

Neurotransmitter Switching Coupled to β-Adrenergic Signaling in Sympathetic Neurons in Prehypertensive States

Overview
Journal Hypertension
Date 2018 Apr 25
PMID 29686017
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Single or combinatorial administration of β-blockers is a mainstay treatment strategy for conditions caused by sympathetic overactivity. Conventional wisdom suggests that the main beneficial effect of β-blockers includes resensitization and restoration of β1-adrenergic signaling pathways in the myocardium, improvements in cardiomyocyte contractility, and reversal of ventricular sensitization. However, emerging evidence indicates that another beneficial effect of β-blockers in disease may reside in sympathetic neurons. We investigated whether β-adrenoceptors are present on postganglionic sympathetic neurons and facilitate neurotransmission in a feed-forward manner. Using a combination of immunocytochemistry, RNA sequencing, Förster resonance energy transfer, and intracellular Ca imaging, we demonstrate the presence of β-adrenoceptors on presynaptic sympathetic neurons in both human and rat stellate ganglia. In diseased neurons from the prehypertensive rat, there was enhanced β-adrenoceptor-mediated signaling predominantly via β-adrenoceptor activation. Moreover, in human and rat neurons, we identified the presence of the epinephrine-synthesizing enzyme PNMT (phenylethanolamine-N-methyltransferase). Using high-pressure liquid chromatography with electrochemical detection, we measured greater epinephrine content and evoked release from the prehypertensive rat cardiac-stellate ganglia. We conclude that neurotransmitter switching resulting in enhanced epinephrine release, may provide presynaptic positive feedback on β-adrenoceptors to promote further release, that leads to greater postsynaptic excitability in disease, before increases in arterial blood pressure. Targeting neuronal β-adrenoceptor downstream signaling could provide therapeutic opportunity to minimize end-organ damage caused by sympathetic overactivity.

Citing Articles

Molecular and cellular neurocardiology in heart disease.

Habecker B, Bers D, Birren S, Chang R, Herring N, Kay M J Physiol. 2024; .

PMID: 38778747 PMC: 11582088. DOI: 10.1113/JP284739.


Circulating noradrenaline leads to release of neuropeptide Y from cardiac sympathetic nerve terminals via activation of β-adrenergic receptors.

van Weperen V, Hoang J, Jani N, Khaky A, Herring N, Smith C J Physiol. 2024; .

PMID: 38352977 PMC: 11322424. DOI: 10.1113/JP285945.


Norepinephrine transporter defects lead to sympathetic hyperactivity in Familial Dysautonomia models.

Wu H, Yu W, Saito-Diaz K, Huang C, Carey J, Lefcort F Nat Commun. 2022; 13(1):7032.

PMID: 36396637 PMC: 9671909. DOI: 10.1038/s41467-022-34811-7.


Cellular basis of learning and memory in the carotid body.

Gold O, Bardsley E, Ponnampalam A, Pauza A, Paton J Front Synaptic Neurosci. 2022; 14:902319.

PMID: 36046221 PMC: 9420943. DOI: 10.3389/fnsyn.2022.902319.


Abnormal Cyclic Nucleotide Signaling at the Outer Mitochondrial Membrane In Sympathetic Neurons During the Early Stages of Hypertension.

Li D, Liu K, Davis H, Robertson C, Neely O, Tarafdar A Hypertension. 2022; 79(7):1374-1384.

PMID: 35506379 PMC: 9172895. DOI: 10.1161/HYPERTENSIONAHA.121.18882.


References
1.
Vaseghi M, Zhou W, Shi J, Ajijola O, Hadaya J, Shivkumar K . Sympathetic innervation of the anterior left ventricular wall by the right and left stellate ganglia. Heart Rhythm. 2012; 9(8):1303-9. DOI: 10.1016/j.hrthm.2012.03.052. View

2.
Kawashima T . The autonomic nervous system of the human heart with special reference to its origin, course, and peripheral distribution. Anat Embryol (Berl). 2005; 209(6):425-38. DOI: 10.1007/s00429-005-0462-1. View

3.
Esler M, Eikelis N, Schlaich M, Lambert G, Alvarenga M, Kaye D . Human sympathetic nerve biology: parallel influences of stress and epigenetics in essential hypertension and panic disorder. Ann N Y Acad Sci. 2009; 1148:338-48. DOI: 10.1196/annals.1410.064. View

4.
Williams R, Bishop T . Selectivity of dobutamine for adrenergic receptor subtypes: in vitro analysis by radioligand binding. J Clin Invest. 1981; 67(6):1703-11. PMC: 370747. DOI: 10.1172/jci110208. View

5.
Zaccolo M, Movsesian M . cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology. Circ Res. 2007; 100(11):1569-78. DOI: 10.1161/CIRCRESAHA.106.144501. View